Calidi Biotherapeutics Aims for IND Filing by Year-End, Expands RedTail Platform
Event summary
- Calidi Biotherapeutics plans to file an IND for CLD-401, its lead RedTail candidate, in Q4 2026.
- 2025 saw $3.1 million debt reduction and $2.3 million in G&A expense cuts.
- New CEO Eric Poma and CMO Guy Travis Clifton joined, along with key advisors.
- Proof-of-concept data expected for RedTail platform in oncology and non-oncology indications.
- Phase I study for CLD-401 anticipated in solid tumors, including NSCLC and TNBC.
The big picture
Calidi Biotherapeutics is positioning itself as a leader in targeted genetic medicines for metastatic diseases. The company's focus on systemic delivery via its RedTail platform addresses a critical gap in treating hard-to-reach tumors. With a strengthened leadership team and improved financial footing, Calidi is poised to compete in the rapidly evolving oncology space, where precision therapies and combination approaches are gaining traction.
What we're watching
- Regulatory Timing
- Whether Calidi can meet its Q4 2026 IND filing target for CLD-401.
- Platform Versatility
- How the RedTail platform's expansion into non-oncology indications progresses.
- Clinical Efficacy
- The pace at which proof-of-concept data emerges for BiTE and T-cell amplifier combinations.
Related topics